Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.57 |
| ▸ | GAPDH | P04406 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590502 | 1.00 | TRPA1 (0.57) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL28911024 | 0.98 | TRPA1 (0.55) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL3280926 | 0.93 | ACHE (0.48) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL3280923 | 0.93 | ACHE (0.48) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL5444137 | 0.91 | PPARG (0.55) | MAPTPPARGGPR132FAAHLTB4R2 | |
| SCHEMBL868400 | 0.84 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL868399 | 0.84 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL13952533 | 0.84 | TRPA1 (0.59) | TRPA1DDAH1GAPDHMAPTPPARG | |
| SCHEMBL3280814 | 0.84 | — | — | |
| SCHEMBL3280819 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254097-A1 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF | STORA ENSO OYJ (FI) | 2024-08-01 | — | — | US | claimed |
| US-20220057384-A1 | SLEEP MODULATION AGENT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-02-24 | — | — | US | claimed |
| EP-3897599-A1 | SLEEP MODULATION AGENT | Oxford University Innovation Limited (GB) | 2021-10-27 | — | — | EP | claimed |
| WO-2020128481-A1 | SLEEP MODULATION AGENT | OXFORD UNIVERSTITY INNOVATION LIMITED (GB) | 2020-06-25 | — | — | WO | claimed |
| US-20030153483-A1 | Concentrated, stable fabric softening composition | TRINH TOAN (US) | 2003-08-14 | — | — | US | claimed |
| EP-0842250-A1 | CONCENTRATED, STABLE FABRIC SOFTENING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997003169-A1 | CONCENTRATED, STABLE FABRIC SOFTENING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1997-01-30 | — | — | WO | claimed |
| CN-116601159-B | Prodrug of aldehyde ketone reductase inhibitor, pimestat disulfide, preparation, pharmaceutical composition and application thereof | 斯洛伐克科学院实验医学中心 | 2026-02-27 | — | — | CN | disclosed |
| US-12208108-B2 | Drug targets of delayed aging and human brain diseases | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240254097-A1 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF | STORA ENSO OYJ (FI) | 2024-08-01 | — | — | US | disclosed |
| EP-4259152-B1 | CEMTIRESTAT DISULFIDE, PRODRUG OF ALDO-KETO REDUCTASE INHIBITOR, PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CENTRUM EXPERIMENTALNEJ MEDICINY SAV V V I (SK) | 2024-06-19 | — | — | EP | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11891370-B2 | Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof | Stora Enso Ojy (FI) | 2024-02-06 | — | — | US | disclosed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070021366-A1 | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2007-01-25 | — | — | US | disclosed |
| US-20070015711-A1 | Administering aromatic cationic peptide for targeted mitochondria; antiischemic, -inflammatory, -arthritic, -diabetic agents, liver disorders, stroke; sepsis; viricides; organ removal; neurogenerative diseases; Parkingson's,Alzheimer's, Huntington's diseases; amyotrophic lateral sclerosis | CORNELL RESEARCH FOUNDATION, INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1722807-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | Cornell Research Foundation Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060110814-A1 | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2006-05-25 | — | — | US | disclosed |
| US-20060084606-A1 | administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ | CORNELL RESEARCH FOUNDATION, INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208108-B2 | Drug targets of delayed aging and human brain diseases | DNM1L, DNM1, DNM2 | TRPA1 4207/4885DDAH1 33/4885GAPDH 1463/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | TRPA1 794/4885DDAH1 2946/4885GAPDH 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.